Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study

Hiroshi Matsuda(Kawamura Gakuen Women's University), Noriko Sato(National Center of Neurology and Psychiatry), Tensho Yamao(Fukushima Medical University), Kenji Ishibashi(Tokyo Metropolitan Institute of Gerontology), Hidehiko Okazawa(University of Fukui), Akinori Takenaka(National Center for Geriatrics and Gerontology), Jun Hatazawa(Osaka University of Pharmaceutical Sciences), Masamichi Ikawa(University of Fukui), Kohei Hanaoka(The University of Osaka), Masahiro Mishina(Nippon Medical School), Sunao Mizumura(Toho University), Kyoji Okita(National Center of Neurology and Psychiatry), Masashi Kameyama(Tokyo Metropolitan Geriatric Hospital), Masayo Ogawa(Alexion Pharma (Switzerland)), Tetsuya Tsujikawa(University of Fukui), Kenji Ishii(Tokyo Metropolitan Institute of Gerontology), Kazunari Ishii(Hyogo Brain and Heart Center), Yoko Shigemoto(National Center of Neurology and Psychiatry), Hayato Kaida(Active Medicine (United Kingdom)), Kengo Ito(National Center for Geriatrics and Gerontology), Takashi Kato(National Center for Geriatrics and Gerontology), Keiko Matsunaga(The University of Osaka), Eku Shimosegawa(The University of Osaka), Miyako Morooka(Toho University), Kenta Miwa(Fukushima Medical University)
Frontiers in Neurology
January 13, 2021
Cited by 50


Related Papers